Nomura/Instinet analyst, Christopher Marai reiterated his Reduce rating on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) and cut his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE